Novartis's patupilone fails pivotal advanced ovarian cancer trial
This article was originally published in Scrip
Executive Summary
Novartis's patupilone (also known as EPO906) did not improve overall survival in a Phase III trial of patients with advanced ovarian cancer refractory or resistant to platinum-based therapy, show top-line results.